Journal profile · Biochemistry, Genetics and Molecular Biology-Genetics
Signal Transduction and Targeted Therapy
ISSN 2095-9907 · eISSN 2059-3635 · Springer Nature · United Kingdom · Founded 2016
Signal Transduction and Targeted Therapy: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 81.24; fully open access; APC about USD 3,790; median 192 days to acceptance (138 articles, last 24 months); 428 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Signal Transduction and Targeted Therapy is published by Springer Nature and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies and Cancer Immunotherapy and Biomarkers, together about 25% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Signal Transduction and Targeted Therapy (ISSN 2059-3635 (online), ISSN 2095-9907 (print), CN 51-1758/R) is an open access journal, which aims to accomplish timely publication of the latest discoveries and progress in both basic science and clinical research related to signal transduction and targeted therapy. It will include research on major human diseases, such as cancer, autoimmune disorders and others. Signal Transduction and Targeted Therapy is a multidisciplinary journal, covering topics including but not limited to molecular biology, cell biology, pharmacology, medicinal chemistry, computational chemistry, systems biology, bioinformatics, and clinical medicine.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-Genetics
Editor-in-chief David KerrPublisher website
Editorial board by country: 59 in mainland China (about 44%); most named Mainland China 59, United States 50, France 3, Hong Kong, China 2, United Kingdom 2 (135 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- SARS-CoV-2 and COVID-19 ResearchMedicine11.3%
- COVID-19 Clinical Research StudiesMedicine7.3%
- Cancer Immunotherapy and BiomarkersMedicine6.3%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology5.6%
- CAR-T cell therapy researchMedicine5.2%
- Immune Cell Function and InteractionImmunology and Microbiology5.1%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology4.7%
- Immune cells in cancerImmunology and Microbiology4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Biochemistry & Molecular Biology | Zone 1 |
| Minor | Cell Biology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Biochemistry & Molecular Biology | Zone 1 |
| Minor | Cell Biology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Biochemistry & Molecular Biology | Zone 1 |
| Minor | Cell Biology | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPMCPubMedPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 81.24LetPub ·
- Impact factor (publisher) 2025
- 81.2Publisher website ·
- 5-year impact factor (publisher) 2025
- 74.6Publisher website ·
- CiteScore 2026-06
- 81.6LetPub ·
- SJR 2026-06
- 17.74LetPub ·
- SNIP 2026-06
- 11.89LetPub ·
- h-index
- 287OpenAlex ·
- i10-index
- 1,891OpenAlex ·
- 2-year mean citedness
- 50.24OpenAlex ·
- Self-citation rate
- 0.5%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 313LetPub ·
- Downloads per year (publisher) 2025
- 26,168,255Publisher website ·
Articles by year OpenAlex count · 2,990 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 418 | 418 | 1,371 |
| 2025 | 428 | 428 | 17,690 |
| 2024 | 370 | 370 | 42,028 |
| 2023 | 469 | 469 | 65,240 |
| 2022 | 403 | 403 | 59,563 |
| 2021 | 443 | 443 | 64,971 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
192 daysMedian, submission to acceptance · P25–P75 129 days – 250 days
- Acceptance to online
- median 48 days (138 articles)
- Submission to online
- median 242 days
- Sample
- 138 articles with submission and acceptance dates (948 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 5 weeksLetPub ·
- Peer review
- Anonymous peer reviewLetPub
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,790 / EUR 3,090 / GBP 2,790 | — | — | |
| LetPub | GBP 2,590 / USD 3,490 / EUR 2,890 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted5
- commentCommentLength not stated
- editorialEditorialLength not stated
- newsNewsLength not stated
- otherOtherLength not stated
- protocolProtocolLength not stated
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- United Kingdom
- Language
- English
- Founded
- 2016
- ISSN
- 2095-9907
- Electronic ISSN
- 2059-3635
- Society / sponsor
- West China Hospital
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Signal Transduction and Targeted Therapy
What CAS zone is Signal Transduction and Targeted Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Signal Transduction and Targeted Therapy is in Zone 1 of Medicine, and in Zone 1 of the minor category Biochemistry & Molecular Biology / Cell Biology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Signal Transduction and Targeted Therapy?
The latest impact factor listed by LetPub is 81.24; CiteScore 81.6, h-index 287.
How long does peer review take at Signal Transduction and Targeted Therapy?
Based on the dates recorded on 138 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 192 days (interquartile range 129–250 days); authors report an average review time of about 5 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Signal Transduction and Targeted Therapy based?
Of the 135 board members whose country the journal's board page names, 59 (about 44%) are in mainland China; the countries named most often are Mainland China (59), United States (50) and France (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Signal Transduction and Targeted Therapy?
According to LetPub and DOAJ records, Signal Transduction and Targeted Therapy is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, PMC and PubMed; that list has not been checked against each database.
Is Signal Transduction and Targeted Therapy open access, and what is the APC?
Signal Transduction and Targeted Therapy is a fully open-access journal. APC about USD 3,790.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .